Abstract
Citalopram, in European studies, has shown some early promise for treatment of poststroke depression and behavioral complications of dementia. An open pilot study of citalopram was conducted in 16 patients with dementia and behavioral disturbances. Citalopram was well tolerated by 13 of the patients, and 9 had a clinically impressive response. A significant overall mean reduction in disruptive vocalizations was observed by means of a novel technique of computer-assisted real-time observation. The mean citalopram plasma level-to-dose ratio was found to be twice that previously reported in younger patients. These pilot findings should encourage future placebo concentration-controlled trials.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Aged
-
Aged, 80 and over
-
Aggression / drug effects
-
Alzheimer Disease / blood
-
Alzheimer Disease / drug therapy*
-
Alzheimer Disease / psychology
-
Biological Availability
-
Citalopram / administration & dosage*
-
Citalopram / adverse effects
-
Citalopram / pharmacokinetics
-
Female
-
Humans
-
Male
-
Middle Aged
-
Pilot Projects
-
Psychomotor Agitation / blood
-
Psychomotor Agitation / drug therapy
-
Psychomotor Agitation / psychology
-
Selective Serotonin Reuptake Inhibitors / administration & dosage*
-
Selective Serotonin Reuptake Inhibitors / adverse effects
-
Selective Serotonin Reuptake Inhibitors / pharmacokinetics
-
Social Behavior Disorders / blood
-
Social Behavior Disorders / drug therapy*
-
Social Behavior Disorders / psychology
-
Social Environment
-
Verbal Behavior
Substances
-
Serotonin Uptake Inhibitors
-
Citalopram